Ocugen Inc (OCGN)
1.78
+0.06
(+3.49%)
USD |
NASDAQ |
May 23, 16:00
1.78
0.00 (0.00%)
After-Hours: 20:00
Ocugen Research and Development Expense (Annual): 39.57M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 39.57M |
| December 31, 2022 | 56.16M |
| December 31, 2021 | 35.11M |
| December 31, 2020 | 6.354M |
| December 31, 2019 | 8.086M |
| December 31, 2018 | 15.63M |
| Date | Value |
|---|---|
| December 31, 2017 | 15.57M |
| December 31, 2016 | 21.58M |
| December 31, 2015 | 23.24M |
| December 31, 2014 | 26.04M |
| December 31, 2013 | 11.95M |
| December 31, 2012 | 11.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
6.354M
Minimum
2020
56.16M
Maximum
2022
29.06M
Average
35.11M
Median
2021
Research and Development Expense (Annual) Benchmarks
| QuidelOrtho Corp | 246.80M |
| Checkpoint Therapeutics Inc | 43.57M |
| Johnson & Johnson | 15.08B |
| Shockwave Medical Inc | 145.65M |
| iBio Inc | 10.33M |